A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control

Abstract

Introduction: Daily dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used with other orally administered antihyperglycemic agents (AHA), as combination therapy, to treat Japanese patients with type 2 diabetes. When combination therapy is indicated, use of a once-weekly (q.w.) orally administered DPP-4 inhibitor might be an appropriate therapeutic option for some patients.

Methods: A 52-week trial was conducted to assess the safety and tolerability (primary objectives) and glycemic efficacy (secondary objectives) of the q.w. DPP-4 inhibitor omarigliptin as add-on therapy to five different classes of orally administered AHA [sulfonylurea (SU), glinide (GL), biguanide (BG), thiazolidinedione (TZD), or α-glucosidase inhibitor (AGI)] commonly used in Japan and having different mechanisms of drug action from DPP-4 inhibitors. The trial consisted of an initial 24-week double-blind, placebo-controlled period during which patients (stratified by background AHA) were randomized to omarigliptin 25 mg q.w. or placebo, followed by a 28-week open-label period during which patients on placebo were switched to omarigliptin.

Results: After 24 weeks, the percentages of patients with adverse events (AEs), serious AEs, drug-related AEs, AEs of symptomatic hypoglycemia, or who discontinued from trial medication because of an AE were generally similar in the omarigliptin and placebo groups, in all background AHA strata and in the overall population. From a mean baseline HbA1c of approximately 8.0%, the placebo-adjusted least-squares mean changes from baseline ranged from -0.80% (AGI stratum) to -1.16% (TZD stratum); p < 0.001 for all background AHA strata. During the open-label period, no safety signals emerged with longer-term treatment. At week 52, the change from baseline in HbA1c in the omarigliptin/omarigliptin group was similar to that of the placebo/omarigliptin group.

Conclusions: Addition of once-weekly omarigliptin to AHA therapy with an SU, GL, BG, TZD, or AGI for up to 52 weeks was generally safe and well tolerated, and provided persistent efficacy.

Clinical trial registration: ClinicalTrials.gov: NCT01697592.

Funding: MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Keywords: Biguanide; DPP-4; Dipeptidyl peptidase-4; Glinide; Incretins; MK-3102; Oral antihyperglycemic agent; Sulfonylurea; Thiazolidinedione; α-Glucosidase inhibitor.

Figures

Fig. 1

Patient disposition weeks 0–52

Fig. 2

HbA1c change from baseline (%) through week 24 by background AHA; a sulfonylurea; b glinide; c biguanide; d thiazolidinedione; e α-glucosidase inhibitor; filled circle omarigliptin, open circle placebo; based on the longitudinal data analysis model described in the “Statistical Analyses” section

Fig. 3

HbA1c change from baseline (%) through week 52 in the omarigliptin/omarigliptin treatment groups by background AHA; filled circle sulfonylurea; open circle glinide; filled inverted triangle biguanide; filled triangle thiazolidinedione; filled square α-glucosidase inhibitor; based on the longitudinal data analysis model described in the “Statistical Analyses” section